What Levamisol Treats: Main Uses and Benefits

The primary therapeutic benefit of Levamisole plays a role in managing distressing symptoms across domains, mainly focused on symptoms associated with acute or episodic changes, and is relevant when supportive symptom management is appropriate in certain chronic conditions.

The use of Levamisole in managing symptoms related to parasitic infections, such as those linked to certain infectious states, is consistent with its established therapeutic applications. It is applied in contexts where additional management of discomfort is required, helping to ease the overall symptom load, such as symptoms related to physical discomfort and systemic imbalance.

Offering Supportive Relief for Heightened Manifestations

In relevant therapeutic contexts, Levamisole may be applied across domains where additional symptomatic support is needed in conditions characterized by periods of heightened symptoms. It is considered relevant for managing symptoms that interfere with daily comfort. The support may assist with maintaining functional stability, offering symptomatic relief that helps patients cope more steadily with difficult, episodic manifestations.

---

Quick Fact: Relevant for Managing Symptom Clusters

Regulatory References

1. EMA PRAC Safety Review

Official Eligibility and Restrictions

Levamisol (Levamisole) eligibility is strictly defined by regulatory guidelines, focusing on absolute contraindications and conditions that require specific caution. The official labeling specifies the populations for whom use is prohibited or restricted based on pre-existing medical conditions and physiological status.

Contraindicated Populations (Cannot Use)

Individuals who must not use Levamisol include those with:

• A documented known hypersensitivity or allergy to Levamisole hydrochloride or any related components.
• Pre-existing blood disorders, such as a history of agranulocytosis.
• Severe renal impairment (severe kidney disease), which is listed as a contraindication in some regulatory documents.

Populations Requiring Conditional Use

Use of Levamisol requires caution and careful consideration in several populations due to potential increased risk, as noted in official prescribing information:

• Hepatic Impairment: Caution is necessary in patients with a history of liver diseases, and dose adjustment may be required.
• Seizure/Autoimmune History: Caution is advised for patients with epilepsy or certain autoimmune conditions, such as rheumatoid arthritis or Sjögren syndrome.
• Existing Infection: Caution is warranted for patients with an existing infection.

Age and Reproductive Status

Levamisol use is established for adult patients and is applied to children for antihelminthic purposes. However, the medicine is generally not recommended for use in pregnant women or those breastfeeding unless the potential benefit is determined to outweigh the potential risks, due to a lack of adequate safety data.

The interaction profile for Levamisol is defined by mandatory administration constraints and documented changes in the systemic exposure of co-administered medicines. The profile includes both pharmacokinetic alterations and pharmacodynamic reinforcement risks.

Interaction Type	Interacting Substance	Official Outcome
Exposure Modification	Warfarin	May increase the anticoagulant effects.
Exposure Modification	Phenytoin	Documented to increase the risk of toxicity.
Bioavailability Alteration	Ivermectin	Increases the systemic availability (bioavailability).
Bioavailability Alteration	Albendazole	Decreases the systemic availability (bioavailability).
Substance Interaction	Alcohol	Causes a disulfiram-like reaction upon co-ingestion.

---

Specific Interaction Restrictions and Conditions

Official documentation establishes strict rules for co-administration with specific classes of substances. Levamisol treatment is formally restricted and must be separated from any use or exposure to Organophosphorus Compounds (such as specific insecticides or anthelmintics) by a mandatory period of 14 days (before or after administration). This separation requirement is a formal regulatory constraint.

Additionally, the drug carries a documented theoretical risk of enhanced toxic effects when combined with other compounds that share a similar action, including Nicotine-like compounds or Cholinesterase Inhibitors. Regulatory documents note that patients with pre-existing blood disorders are contraindicated for this medication, a crucial consideration for interaction-related risk assessment. Furthermore, there is a documented potential for increased systemic exposure in patients with hepatic impairment due to reduced clearance. The overall interaction profile centers on time-based prohibitions and managing potential drug concentration changes.

How Levamisol Works: Mechanism of Action

The pharmacological action of Levamisole is exerted through two fundamentally different and independent biological mechanisms: a direct molecular action against parasitic cells and a modulation of specific signaling processes within the host's immune system.

Dual Mechanism 1: Nicotinic Agonism and Parasite Paralysis

The antihelminthic action stems from the compound's highly selective direct agonism on the L-subtype nicotinic acetylcholine receptors on susceptible nematode muscle cells. This interaction causes continuous, unregulated influx of ions across the muscle cell membrane, leading to sustained muscle depolarization. The resulting physiological state is an irreversible, spastic paralysis of the worm, facilitating its subsequent physical displacement by intestinal peristalsis.

Dual Mechanism 2: Modulation of T-Lymphocyte and Macrophage Processes

The immunomodulatory mechanism, active when cellular immune activity is diminished, involves the modulation of key host immune cells. Levamisole promotes the activity of T-lymphocytes and macrophages by influencing their maturation and increasing the production of signaling molecules, such as Interferon-gamma. This mechanism mediates the re-establishment of activity within cellular immune processes.

How to Use Levamisol

The usage of Levamisole is defined by standard pharmaceutical protocols, indicating the medicine to be taken via the oral route using available tablet formulations. The dosing regimen is determined by the intended course of treatment, resulting in two primary administration patterns based on label-specified instructions.

For the short-term acute course, typically associated with antihelminthic use, the instruction for adults is a single oral dose generally ranging from 120 mg to 150 mg of Levamisole base equivalent. This pattern may specify a repeat administration after seven days, depending on the prescribing information.

The second pattern involves a cyclic, long-term course, based on labeled adjuvant protocols, which is administered as 50 mg three times daily (TID) for three consecutive days. This three-day schedule is then repeated at regular intervals, such as every two weeks, potentially continuing for up to one year.

Dose adjustments for specific patient groups are also documented in standard product labeling. The pediatric dose for the antihelminthic regimen is typically set at 3 mg per kg of body weight, also given as a single oral dose. For patients with stable renal impairment (GFR > 10 mL/min), the dosage is generally maintained. A key procedural instruction for the cyclic regimen is that a missed dose should be skipped to preserve the regular schedule, and the subsequent dose must not be doubled.

Research evidence / Overview of studies for Levamisol

The available research on Levamisol was studied for its historical and currently researched applications, with the evidence base differing across these various contexts. The findings describe group patterns observed during studies and studies help show what has has been observed so far, but research does not determine whether an individual will respond similarly.

---

Evidence for the Anthelmintic Role in Parasitic Worm Infections

Research was studied for conditions associated with acute or disruptive episodes linked to specific parasites, primarily through short-term clinical trials. These studies examined outcomes related to physical discomfort and systemic or functional imbalance, specifically by measuring the parasite clearance rate in affected adults and children. The reported outcomes were consistently focused on acute, short-term success in clearing the immediate infection.

However, the evidence base is widespread but often basic-level. Long-term effects are not fully established regarding sustained parasite clearance, and there is limited information for long-term outcomes after the initial course. Comparative evidence is lacking in modern, high-quality trials.

---

Evidence for its Role for conditions characterized by fluctuating or episodic manifestations in Pediatric Kidney Conditions

Research was evaluated in numerous randomized controlled trials (RCTs) and meta-analyses to understand its role in children who have conditions characterized by fluctuating or episodic manifestations, specifically frequently relapsing or steroid-dependent Nephrotic Syndrome. Research explored outcomes focusing on the period until a return of heightened symptoms and the proportion of children remaining in stable status over defined time intervals.

Findings indicate patterns observed in the studies where the period until a return of heightened symptoms was observed to be longer in one study group compared to the placebo group. The overall certainty of the evidence for the outcomes related to long-term periods without a return of heightened symptoms often remains low to moderate when assessed by comprehensive reviews, due in part to high variability found across the trial designs. Additionally, the follow-up durations were limited in many studies.

Key Studies & References

1. Levamisole - Electronic Essential Medicines List (Anthelmintic Use)
2. Levamisole hydrochloride - NCI Drug Dictionary - National Cancer Institute
3. PRAC starts safety review of levamisole, a medicine used to treat parasitic worm infections (Regulatory/Safety)

Common questions about Levamisol (FAQ)

Q: What is the main approved use of Levamisol in the US or EU?

According to official regulatory documents, Levamisol is currently authorized in some European Union countries for the treatment of parasitic worm infections (anthelmintic use). It is noted that the drug was previously approved in the United States for colon cancer but has since been withdrawn from the US market.

Q: How quickly does Levamisol usually start working?

Official product information describes the anti-parasitic effect as acting rapidly, often leading to the paralysis of worms within seconds of contact. This effect facilitates the physical expulsion of the parasites, which is typically observed within 24 hours following administration.

Q: Does taking Levamisol make you feel tired or sleepy?

Official adverse event reporting indicates that drowsiness and fatigue are possible side effects. Official documents suggest that if these effects become severe, they should be discussed with a healthcare professional.

Q: Can Levamisol be taken at the same time as cold and flu medicine?

Official safety guidance indicates that a healthcare professional should be informed about all medicines being taken, which includes over-the-counter (OTC) drugs like cold and flu preparations. This is the standard regulatory procedure for assessing the potential risk of an interaction before co-administration.

Q: Are there any specific foods or drinks to avoid while taking Levamisol?

According to official patient information, the medicine can generally be taken with or without food, as directed by a healthcare professional. There are no known interactions documented with specific types of food.

Q: Where can I find the official regulatory document (like FDA or EMA) about Levamisol?

Official drug labels and prescribing information, such as the FDA DailyMed label or the EMA Summary of Product Characteristics (SmPC), are available on the respective government drug agency's public database. These sources provide detailed, comprehensive regulatory information about the medicine.

Q: Does Levamisol have a potential for causing weight gain or loss?

Official adverse reaction reports have included decreased appetite and anorexia as possible side effects of the medicine. However, weight gain or loss itself is not consistently listed as a primary adverse reaction in the official documentation.

Q: How long after starting Levamisol can I expect to see its full effect?

The duration of the full clinical effect in the body is not clinically established in the available official documentation. This means there is no defined timeframe in the official sources for when to expect the overall full therapeutic effect.

Q: What is the safety classification of Levamisol for general public use?

Levamisol is a medicine that is generally available only with a doctor's prescription. The World Health Organization (WHO) also includes Levamisol on its List of Essential Medicines for certain purposes.

Q: Are there any long-term side effects associated with taking Levamisol?

Regulatory and post-marketing reports indicate a risk of potentially long-term complications associated with the medicine. These include serious issues such as chronic blood disorders and effects on the nervous system, such as leukoencephalopathy (brain dysfunction).

Q: Is a prescription required to get Levamisol in most countries?

Official guidance uniformly states that the medicine is available only with a doctor's prescription to ensure appropriate medical oversight of its use.

Q: Are there different brand names for the medicine Levamisol?

The drug has been marketed globally under various brand names, such as Ergamisol® (US/Canada, though discontinued for human use) and Decaris or Levamisol Arena in other regions. These products contain the same active ingredient, Levamisol hydrochloride.

Q: Can older adults generally use Levamisol?

Official prescribing information notes that the medicine has been used in elderly patients. It is not expected to cause different side effects or problems compared to younger adults, although specific comparative data for this population is limited.

Q: Does the time of day matter when taking Levamisol?

The official instructions prioritize following the exact prescribed dosing regimen, which might be a single dose or a specific cyclic schedule. The medicine can be taken with or without food, indicating that adherence to the schedule is the most critical factor, rather than a specific time of day.

Q: What is the difference between the 'on-label' use and other reported uses of Levamisol?

The on-label use refers to the medical indications that have been specifically approved by regulatory bodies, such as the anthelmintic use in the EU. Other applications that are not approved or supported by official agencies are often described as off-label use in regulatory and medical literature.

Q: What is the maximum duration of treatment with Levamisol described in official prescribing information?

The treatment duration varies depending on the medical purpose. For the acute anti-parasitic regimen, it is often a single dose. For one former cyclic regimen (adjuvant therapy), the maintenance course was described in official labeling as continuing for up to 1 year at regular intervals.

Q: Is it true that Levamisol was withdrawn or is restricted in some areas?

Yes, official regulatory history indicates the medicine was withdrawn from the US market due to concerns about its safety profile. However, it remains authorized for anthelmintic use in some European Union countries and other parts of the world.

Q: Can Levamisol be taken with common over-the-counter pain relievers?

Regulatory guidance indicates that a healthcare professional should be informed about all products being taken, including common over-the-counter (OTC) pain relievers. This is necessary to assess the potential for drug-drug interactions.

Q: Are there any reports of Levamisol causing confusion or mood changes?

Official adverse event reports have included effects such as confusion and increased irritability. Serious nervous system effects are documented risks which can sometimes lead to impaired cognition.

Q: Does Levamisol interact with common supplements like vitamins or herbal remedies?

Regulatory safety guidance suggests that the use of the medicine should be discussed with a healthcare professional, specifically noting the importance of mentioning vitamins, herbal remedies, and supplements. This is to ensure that all potential interactions are considered during the course of treatment.

Q: Is Levamisol associated with any warnings regarding driving or operating machinery?

Official warnings indicate that performing activities that require alertness, such as driving or operating machinery, should be avoided if side effects like dizziness or sleepiness occur. These warnings are based on the documented central nervous system effects of the medicine.

Q: What is the difference in how Levamisol is used for humans versus animals?

The drug is used in both human and animal health contexts. In the United States, it is an approved drug primarily for veterinary medicine (as an anthelmintic). In other global regions, it is used for human health for its anti-parasitic and immunomodulatory properties.

Q: Where can I find patient information leaflets or consumer medication guides for Levamisol?

Patient information leaflets or consumer medication guides are typically available through the official regulatory websites that publish the drug label, such as DailyMed (FDA). These documents should also be available from the dispensing pharmacy.

Q: Can Levamisol affect fertility?

Official patient information states that the medicine may temporarily or permanently affect the ability to have children in both men and women. This is an important safety consideration documented in the official regulatory texts.

Levamisole storage and disposal must comply with conditions established in regulatory documents to ensure product stability and prevent environmental harm.

Official Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature, generally 20°C to 25°C (68°F to 77°F).
Protection	Keep container tightly closed, protected from light, and away from heat.
Child Safety	KEEP OUT OF REACH OF CHILDREN and stored locked up.

Disposal Instructions

Official disposal procedures mandate that unused Levamisole must be disposed of according to local, regional, and national regulations, typically through an approved waste disposal plant. The product must not be released to the environment and disposal should avoid drains or sewer systems, as stated in regulatory and safety documents. This measure ensures safe waste management.